Loading color scheme

Ecosystem Startup

Scioto Biosciences is advancing a proprietary Activated Bacterial Therapeutics (ABT) platform for delivering best-in-class, live therapeutic bacteria to the gut. Scioto’s lead candidate, SB-121, has the potential to reduce disease burden in any disorder associated with a “leaky gut,” including clostridium difficile infections, irritable bowel syndrome, diabetes, oncology and various other chronic diseases. 

Innovation Space:
Microbiome, Inflammation, Neurology

Latest News